hrp0084p2-296 | Diabetes | ESPE2015

Children Born from Mother with Gestational Diabetes Mellitus are at Higher Risk in Metabolic Syndrome

Horikawa Reiko , Arata Naoko , Naiki Yasuhiro

Background: The metabolic outcome in adult life is known to be determined during fetal life. Prenatal poor nutrition also affects growth and maturation, formation of insulin resistance during childhood. Little is known about the effect of maternal gestational diabetes mellitus (GDM) on early metabolic and growth outcome of their children.Objective and hypotheses: To investigate growth, glucose metabolism, and blood pressure in children of mothers with GD...

hrp0094p2-280 | Growth and syndromes (to include Turner syndrome) | ESPE2021

Outcomes in growth hormone-treated Noonan syndrome children: impact of PTPN11 mutation status

AL Jorge Alexander , Pietropoli Alberto , Kelepouris Nicky , Horikawa Reiko ,

Objectives: Mutations in PTPN11 are known to be associated with Noonan syndrome (NS), accounting for approximately 50% of cases. Data from a non-interventional and phase 3 study of Norditropin (somatropin; Novo Nordisk A/S, Denmark) were used to assess the impact of PTPN11 mutation status on growth outcomes in children with NS receiving growth hormone therapy (GHT).Methods: The ANSWER (NCT01009905) prog...

hrp0092p1-406 | Pituitary, Neuroendocrinology and Puberty (2) | ESPE2019

Tolvaptan for Management of Intractable Salt and Water Imbalance in a Case with Suprasellar Tumor after Surgery

Yamaguchi Tomoe , Terashita Shintaro , Kinjo Kenichi , Fujisawa Yusuke , Yoshii Keisuke , Naiki Yasuhiro , Horikawa Reiko

Background: It is sometimes difficult to diagnose and manage fluid and electrolyte imbalance after surgery for hypothalamic/pituitary tumors. We present a pediatric case of severe SIADH successfully treated with tolvaptan after suprasellar tumor resection.Case: The case was 8-year-old girl with growth failure. She was found to have suprasellar tumor on CT scan when she accidentally fell down and hit her head. MRI suggest...

hrp0092lb-1 | Late Breaking Posters | ESPE2019

A Trial Investigating the Long-Term Efficacy and Safety of Two Doses of Norditropin® (Somatropin; Recombinant Human Growth Hormone) in Japanese Children with Short Stature Due to Noonan Syndrome Over Four Years of Treatment

Horikawa Reiko , Ogata Tsutomu , Matsubara Yoichi , Yokoya Susumu , Ogawa Yoshihisa , Nishijima Keiji , Endo Takaaki , Ozono Keiichi

Objectives: This trial (NCT01927861) evaluated the growth-promoting effect and safety of Norditropin® (somatropin; recombinant human growth hormone) in Japanese children with short stature due to Noonan syndrome over four years of treatment.Methods: Pre-pubertal children diagnosed with Noonan syndrome were randomized 1:1 to receive Norditropin® 0.033 mg/kg/day or 0.066 mg/kg/day. Change in...

hrp0089fc10.2 | Late Breaking | ESPE2018

Efficacy and Safety of Once-Weekly Somapacitan in Childhood Growth Hormone Deficiency: Results of a Randomised Open-Label, Controlled Phase 2 Trial

Savendal Lars , Rasmussen Michael , Horikawa Reiko , Khadilkar Vaman , Battelino Tadej , Saenger Paul

Background: Growth hormone deficiency (GHD) requires long-term daily injections with GH replacement therapy and is associated with considerable treatment burden by patients and caregivers. Somapacitan is a long-acting GH derivative that is being developed for once-weekly dosing in adults and children with GHD. A well-established protraction method, which is successfully in use to extend the half-life of insulin and glucagon-like peptide (GLP)-1, has been applied in developing ...

hrp0082p2-d1-571 | Sex Development | ESPE2014

Identification of a Missense MAP3K1 Mutation in a Patient with Hypospadias

Igarashi Maki , Horikawa Reiko , Nakabayashi Kazuhiko , Hata Kenichirou , Ogata Tsutomu , Fukami Maki

Background: Recently, eight MAP3K1 mutations have been identified in patients with 46,XY disorder of sex development (DSD), although detailed clinical findings of the mutation-positive patients remain to be investigated.Objective and hypotheses: To clarify the frequency and clinical consequences of MAP3K1 mutations.Method: Mutation screening of MAP3K1 were performed for 37 patients with 46,XY DSD. Phenoty...

hrp0094fc9.3 | Growth Hormone and IGFs | ESPE2021

Once-weekly somapacitan versus daily growth hormone in growth hormone deficiency: 3 year efficacy and safety results from REAL 3, a randomised controlled phase 2 trial

Savendahl Lars , Battelino Tadej , Rasmussen Michael Hojby , Saenger Paul , Horikawa Reiko ,

Growth hormone (GH) replacement therapy currently requires daily subcutaneous injections. Somapacitan is a long-acting GH-derivative in development for once-weekly use in children with GH deficiency (GHD). A phase 2, multinational, randomised, open-label, controlled trial (NCT02616562) investigated the efficacy and safety of somapacitan compared with daily GH (Norditropin®). GH-treatment-naïve prepubertal children with GHD received 0.04 (n = 16), 0.08 (n...

hrp0095p1-393 | Thyroid | ESPE2022

Urinary Iodine Concentration and Thyroid Function in Children by Age

Igarashi Mizuho , Kashima Takemoto , Hibiki Doi , Yoshii Keisuke , Naiki Yasuhiro , Horikawa Reiko

Background: There are few reports on age-related differences in urinary iodine concentrations, which reflect iodine intake.Objective: We investigated the relationship between age-related differences in urinary iodine concentration and thyroid function.Methods: The subjects were 749 children aged 1 year, 677 children aged 3 years (excluding 2 children aged 3 years whose urinary iodi...

hrp0095p1-108 | Growth and Syndromes | ESPE2022

Efficacy, Observer-Reported Outcomes, and Safety of Once-Weekly Somapacitan in Children with Growth Hormone Deficiency (GHD): 4-Year Results from the REAL 3 Trial

Sävendahl Lars , Battelino Tadej , Højby Rasmussen Michael , Brod Meryl , Wai Lee Kai , Saenger Paul , Horikawa Reiko

Children with GHD are currently treated with daily subcutaneous growth hormone (GH) injections, which can be burdensome. Somapacitan is a long-acting GH derivative in development for once-weekly use in children with GHD. REAL 3 (NCT02616562) is a phase 2, multinational, randomised, open label, controlled trial assessing efficacy and safety of somapacitan vs daily GH (Norditropin®). Prepubertal, GH-naïve children with GHD received 0.04 (n=16), 0.08 (n</e...

hrp0092fc14.5 | GH and IGF5 | ESPE2019

OOnce-weekly Somapacitan vs Daily Growth Hormone (Norditropin®) in Childhood Growth Hormone Deficiency: One-year Results from a Randomised Phase 2 Trial

Sävendahl Lars , Battelino Tadej , Horikawa Reiko , Juul Rasmus Vestergaard , Rasmussen Michael Højby , Saenger Paul

Daily injections are required for human growth hormone (GH) replacement therapy. Somapacitan is a long-acting GH derivative being developed for once-weekly dosing in adults and children using a proven protraction method, currently successfully in use to extend the half-life of insulin and glucagon-like peptide 1.To evaluate the efficacy and safety of three different once-weekly somapacitan doses compared with Norditropin®, a daily GH, ove...